Healthy
Conditions
Keywords
volunteers
Brief summary
This is a randomized, single-blind, controlled, single centre bronchoscopy study designed to assess the effects of fluticasone propionate on airway gene expression and cellularity in healthy adult controls without asthma.
Detailed description
This is a randomized, single-blind, controlled, single centre bronchoscopy study designed to assess the effects of fluticasone propionate on airway gene expression and cellularity in healthy adult controls without asthma. This study will allow a more accurate assessment of the changes in gene/protein expression and cellularity that drive severe treatment-resistant asthma by allowing for the effects that are due to corticosteroids rather than the disease to be considered. This improved mechanistic understanding is important to identify novel therapeutic targets in severe asthma, and to support the development of novel therapeutics. The primary endpoint is the corticosteroid-inducible gene expression pattern in healthy airways. Approximately 30 healthy adult subjects (age 18-65) will be randomised in a 2:1 ratio to one of two study groups: i) patients will receive fluticasone propionate 500 mcg b.i.d. via Accuhaler for 4 weeks (n=20), or ii) patients will receive no treatment for 4 weeks (n=10). Bronchoscopy will be performed in all patients at baseline, prior to the start of the treatment period and at the end of week 4. The PI, Genentech and Leicester laboratory support staff will be blinded to treatment allocation. A control arm is included to assess the repeatability of the planned analyses, the stability of the gene expression profiles measured during this study period, and to provide a comparator to the treatment group. Written informed consent for participation in the study must be obtained before performing any study-specific tests or evaluations. Consent will be obtained at the screening visit. At screening, important co-morbidities will excluded . Patients will also be randomised at this screening visit. To ensure there are sufficient data for analysis, if a subject withdraws before completion of the study, they will be replaced with another subject.
Interventions
DRUGFluticasone propionate
Flixotide Accuhaler 500 micrograms b.i.d.
DEVICEAccuhaler
Flixotide Accuhaler 500 micrograms b.i.d.
Sponsors
University Hospitals, Leicester
Genentech, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Participant willing and able to give informed consent * Male or Female, aged 18-65 years at Visit 1 * Forced expiratory volume at one second (FEV1) \>80% predicted * FEV1/forced vital capacity (FVC) ratio ≥70% * Non-smoker for \>1 year with \<10 py smoking history * Female participants of child bearing potential must ensure use of effective contraception during the study * Participants has clinically acceptable laboratory and ECG at screening * A chest x-ray confirming the absence of significant lung disease * A negative result to skin prick testing with common aeroallergens, or, if a skin prick test to a common aeroallergen is positive, a negative response to challenge with methacholine (defined as a provocative concentration causing a 20% fall in FEV1 \[PC20 methacholine\] \>16 mg/ml) * Able (in the Investigators opinion) and willing to comply with all study requirements
Exclusion criteria
* Failure to meet the inclusion criteria * Female participants who are pregnant, lactating or planning pregnancy during the course of the study * History of a severe allergic reaction or anaphylaxis to corticosteroids * Systemic treatment with corticosteroids within last 6 months * Any infection that resulted in hospital admission for ≥ 24 hours within 4 weeks prior to Visit 1 or during screening * Any infection that required treatment with IV or intramuscular (IM) antibiotics within 4 weeks prior to Visit 1 or during screening * Any active infection that required treatment with oral antibiotics within 2 weeks prior to Visit 1 or during screening * Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening * Active tuberculosis requiring treatment within 12 months prior to Visit 1 * Known immunodeficiency including but not limited to HIV infection * Evidence of acute or chronic hepatitis or known liver cirrhosis * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin elevation ≥2.0 × the upper limit of normal (ULN) during screening * Clinically significant abnormality on screening ECG or laboratory tests (haematology, serum chemistry, and urinalysis) that, in the opinion of the investigator, may pose an additional risk in administering study drug to the patient or performing bronchoscopy * Known current malignancy or current evaluation for a potential malignancy * Unable to safely undergo elective flexible fiberoptic bronchoscopy because of any one of the following: * History of allergic reaction to local anesthetics to be used during the bronchoscopy * Presence of clinically significant abnormality on Screening Coagulation Panel * Presence of clinically significant medical comorbidities that, in the opinion of the investigator, may make the patient unsuitable for elective bronchoscopy or would impact on study efficacy assessments * A history of atopic disease (allergic rhinitis \[perennial or seasonal\], atopic dermatitis, food allergy) * History of alcohol or drug abuse that would impair or risk the patient's full participation in the study, in the opinion of the investigator * Current smoker, former smoker with smoking history of \>10 pack-years. * Treatment with anticoagulant medications including but not limited to aspirin,warfarin or antiplatelet medication * Use of a licensed or investigational monoclonal antibody within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) * Use of a systemic immunomodulatory or immunosuppressive therapy within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer). * Use of other investigational therapy not described above within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) * Receipt of a live attenuated vaccine within 4 weeks prior to Visit 1 * Use of complementary, alternative, or homeopathic medicines including, but not limited to traditional or non-traditional herbal medications within 3 months * Scheduled elective surgery or other procedures requiring general anaesthesia during the study * Donation of blood during the study or within the past 12 weeks * BMI \>38 kg/m2 * Body weight \<40 kg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative change from baseline in airway tissue gene expression following 4-weeks of inhaled fluticasone propionate treatment | 6 months after last patient visit |
Secondary
| Measure | Time frame |
|---|---|
| Relative change from baseline in airway cellularity following 4-weeks of inhaled fluticasone propionate treatment | 18 months after last patient visit |
| Relative change from baseline in airway protein expression following 4-weeks of inhaled fluticasone propionate treatment | 18 months after last patient visit |
| Relative change from baseline in peripheral blood gene expression following 4-weeks of inhaled fluticasone propionate treatment | 18 months after last patient visit |
| Differentiate pathways, biomarkers, and heterogeneity between gene expression and pathophysiology in severe asthmatics on ICS +/- lebrikizumab (separate Genentech-sponsored study known as CLAVIER) and healthy volunteers on ICS | 18 months after last patient visit |
Countries
United Kingdom
Contacts
PRINCIPAL_INVESTIGATORPeter Bradding, DM
University of Leicester/University Hospitals of Leicester NHS Trust
Outcome results
None listed